Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.
Journal of Clinical Oncology (2017)
  • Colleen Dorsey, Abramson Cancer Center, Philadelphia, PA;
  • Dana Paskalis, TG Therapeutics, Inc., Manhattan, NY;
  • Danielle M. Brander, Duke University
  • Frederick Lansigan, Dartmouth–Hitchcock Medical Center
  • Paul M. Barr, University of Rochester Medical Center
  • Nicole Lamanna, Columbia University Medical Center
  • Bruce D. Cheson, Georgetown University
  • Jeffrey J. Pu, Penn State Cancer Institute
  • Marshall T. Schreeder, Clearview Cancer Institute, Huntsville, AL;
  • John M. Pagel, Swedish Cancer Institute, Seattle, WA;
  • Peter Sportelli, TG Therapeutics, Inc., New York, NY;
  • Molly J Fanning, Abramson Cancer Center, Philadelphia, PA;
  • Hari P. Miskin, TG Therapeutics, Inc., New York, NY;
  • Tracey Zimmer, Hospital of the University of Pennsylvania
  • Kristy Walsh, Abramson Cancer Center, Philadelphia, PA;
  • Stephen J. Schuster, Abramson Cancer Center, Philadelphia, PA;
  • Eline T. Luning-Prak, University of Pennsylvania
  • E. Paul Wileyto, University of Pennsylvania
  • Michael S. Weiss, TG Therapeutics, Inc., New York, NY;
  • Anthony R. Mato, University of Pennsylvania
Link
Disciplines
Publication Date
May 20, 2017
DOI
10.1200/jco.2017.35.15_suppl.tps7569
Citation Information
Colleen Dorsey, Dana Paskalis, Danielle M. Brander, Frederick Lansigan, et al.. "KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy." Journal of Clinical Oncology Vol. 35 (2017)
Available at: http://works.bepress.com/john-pagel/304/